NCT01906385
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
At risk: Primary completion moved at least 1 year 3 months later.
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 33 versions: 28 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Site details revised at 4 of 4 sites
Notable Primary and study completion pushed from Dec 2025 to Apr 2027 Show 5 more changesShow less
- Lead sponsor: Plus Therapeutics to Cerenome
- Eligibility criteria expanded, about 45 words
- Study sites: 3 to 4
- Secondary endpoints: details revised at 2 of 9 entries
- Publications: details revised at 1 of 1 entry
- Notable Primary and study completion dates: Jan 2025 to Dec 2025
- Site contacts updated at 1 of 3 sites
- Minor Study sites: 2 to 3v30
- Minor Study sites: 3 to 2v29
Show 22 earlier versionsHide 22 earlier versions
- Minor Site contacts updated at 1 of 3 sitesv27
- Notable Eligibility criteria expanded, about 162 words
- Primary endpoints: 1 to 2
- Secondary endpoints: 3 to 9
- Study description expanded, about 96 words
- Notable Eligibility criteria expanded, about 8 words
- Study description expanded, about 128 words
- Site contacts updated at 1 of 3 sites
- Minor Site contacts updated at 1 of 3 sitesv22
- Minor Site details revised at 1 of 3 sitesv21
- Minor Site details revised at 1 of 3 sitesv20
- Minor Site details revised at 1 of 3 sitesv19
- Minor Site contacts updated at 2 of 3 sitesv18
- Minor Study title expanded, about 1 wordv17
- Minor Site details revised at 1 of 3 sitesv16
- Notable Lead sponsor: The University of Texas Health Science Center at San Antonio to Plus Therapeuticsv15
Notable Lead sponsor: Andrew Brenner to The University of Texas Health Science Center at San Antoniov14 Show 5 more changesShow less
- Enrollment target: 30 to 55
- Eligibility criteria expanded, about 12 words
- Study sites: 1 to 3
- Secondary endpoints: details revised at 1 of 3 entries
- Collaborators expanded, about 4 words
Notable Primary and study completion dates: Jan 2020 to Jan 2025v13 Show 4 more changesShow less
- Start date: Mar 2015 to Jun 3, 2015
- Eligibility criteria expanded, about 58 words
- Study description shortened, about 327 words
- Study title revised
- Notable Primary and study completion dates: Jan 2019 to Jan 2020v12
- Minor Primary and study completion dates pushed to Jan 2019v11
- Minor Interventions: Rhenium Liposome Treatment (Radiation) to Rhenium Liposome Treatment (Drug)v10
- Notable Primary completion date: Aug 2017 to Aug 2018
- Study completion date: Dec 2017 to Dec 2018
- Minor Primary completion date: Mar 2017 to Aug 2017v8
- Notable Trial status: Not Yet Recruiting to Recruiting
- Site details revised
- Notable Start date: Dec 2014 to Mar 2015v4
- Notable Start date: Mar 2014 to Dec 2014
- Study arms: 0 to 1
- Notable Start date: Oct 2013 to Mar 2014
- Primary completion date: Oct 2016 to Mar 2017
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (9)
Show 4 moreShow less
Arms and interventions
Arm Phase I: Experimental: Dose Escalation for Cohorts 1-8 Each participant will receive a single administration of 186RNL. At each dose level, a minimum of three to a maximum of six participants will be enrolled. If no dose limiting toxicity is observed in the initial three participants, then the next higher dose level cohort will open for enrollment. The dose escalation scheme will follow a modified Fibonacci dose escalation scheme as shown below: COHORT ACTIVITY Cohort 1 (1.0 mCi) Cohort 2 (2.0 mCi) Cohort 3 (4.0 mCi) Cohort 4 (8.0 mCi) Cohort 5 (13.4 mCi) Cohort 6 (22.3 mCi) Cohort 7 (31.2 mCi) Cohort 8 (41.5 mCi) Phase 2: Single arm, prospective study utilizing a non-DLT dose obtained from the dose escalation portion of IND 116117, NIH-NCI Grant (22.3 mCi (total 186RNL activity) at a concentration of 2.5 mCi/mL and 8.8 mL total volume).
Drugs: Rhenium Liposome Treatment
Sites
4 sites in 1 country